CRISPR Therapeutics AG
CRSP
$43.34
-$2.19-4.81%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -366.25M | -239.59M | -265.80M | -217.14M | -153.61M |
| Total Depreciation and Amortization | 19.26M | 19.32M | 19.50M | 19.62M | 19.84M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 47.95M | 54.81M | 54.97M | 58.10M | 66.98M |
| Change in Net Operating Assets | 156.27M | -23.35M | 69.57M | -20.00M | -193.59M |
| Cash from Operations | -142.77M | -188.82M | -121.76M | -159.42M | -260.38M |
| Capital Expenditure | -1.90M | -2.39M | -4.28M | -7.13M | -9.47M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -278.58M | -465.38M | -180.53M | 166.15M | 384.12M |
| Cash from Investing | -280.48M | -467.76M | -184.81M | 159.02M | 374.65M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 332.45M | 354.51M | 346.43M | 363.19M | 62.66M |
| Repurchase of Common Stock | -466.00K | -466.00K | -466.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 331.98M | 354.05M | 345.96M | 363.19M | 62.66M |
| Foreign Exchange rate Adjustments | -21.00K | 127.00K | 4.00K | 30.00K | 73.00K |
| Miscellaneous Cash Flow Adjustments | -- | -1.00K | -1.00K | -1.00K | -1.00K |
| Net Change in Cash | -91.29M | -302.41M | 39.40M | 362.82M | 177.01M |
